MedDataX Logo

Non-interventional Observational Study With Viramune (Nevirapine) and Various Drug Combinations in the Antiretroviral Combination Treatment of HIV-infected Patients Who Have Already Been Treated for Approx. 10 Years With Viramune

NCT ID: NCT00979420

Last Updated: 2014-06-30

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Study Classification

OBSERVATIONAL

Study Start Date

2009-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The question that prompted this study is the extent to which results from clinical trials can be translated into everyday practice (external validity). An observation period of about 10 years extends far beyond the duration of clinical trials. First and foremost are questions about tolerability and the efficacy of an antiretroviral combination treatment with Viramune and other antiretroviral partners. In particular, adverse events will be recorded and the therapeutic effect will be monitored via the course of viral load and improvement of the immune system, based on the CD4 cell count.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Non-Interventional Observational Study With Viramune Plus Antiretroviral in HIV Infected Patients

NCT00876733

HIV Infections
COMPLETED

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

NCT01524900

HIV Infections
COMPLETED

Observational Non-interventional Study With Viramune® in Combination With Truvada® in HIV-infected Patients

NCT00543803

HIV Infections
COMPLETED

Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients

NCT00819052

HIV Infections
COMPLETED PHASE3

Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese Patients:Multicentric Observation Cohort

NCT00618176

HIV Infections
COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Design:

observational

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HIV treatment

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Inclusion criteria The inclusion criteria for treatment with Viramune plus other antiretroviral combination drugs are to be based on the current Information for Healthcare Professionals/SPC (R08-0843)

Exclusion criteria The exclusion criteria for treatment with Viramune plus other antiretroviral combination drugs are to be based on the current Information for Healthcare Professionals/SPC (R08-0843).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Boehringer Ingelheim

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Boehringer Ingelheim Investigational Site 1

Aachen, , Germany

Site Status

Boehringer Ingelheim Investigational Site 10

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 11

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 12

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 13

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 14

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 15

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 2

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 3

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 4

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 5

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 6

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 7

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 8

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 9

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 16

Bochum, , Germany

Site Status

Boehringer Ingelheim Investigational Site 17

Bonn, , Germany

Site Status

Boehringer Ingelheim Investigational Site 18

Bremen, , Germany

Site Status

Boehringer Ingelheim Investigational Site 19

Dortmund, , Germany

Site Status

Boehringer Ingelheim Investigational Site 20

Duisburg, , Germany

Site Status

Boehringer Ingelheim Investigational Site 21

Düsseldorf, , Germany

Site Status

Boehringer Ingelheim Investigational Site 22

Düsseldorf, , Germany

Site Status

Boehringer Ingelheim Investigational Site 23

Düsseldorf, , Germany

Site Status

Boehringer Ingelheim Investigational Site 24

Düsseldorf, , Germany

Site Status

Boehringer Ingelheim Investigational Site 25

Frankfurt, , Germany

Site Status

Boehringer Ingelheim Investigational Site 26

Frankfurt, , Germany

Site Status

Boehringer Ingelheim Investigational Site 27

Frankfurt, , Germany

Site Status

Boehringer Ingelheim Investigational Site 28

Freiburg im Breisgau, , Germany

Site Status

Boehringer Ingelheim Investigational Site 29

Freiburg im Breisgau, , Germany

Site Status

Boehringer Ingelheim Investigational Site 30

Freiburg im Breisgau, , Germany

Site Status

Boehringer Ingelheim Investigational Site 31

Hamburg, , Germany

Site Status

Boehringer Ingelheim Investigational Site 32

Hamburg, , Germany

Site Status

Boehringer Ingelheim Investigational Site 33

Hamburg, , Germany

Site Status

Boehringer Ingelheim Investigational Site 34

Hamburg, , Germany

Site Status

Boehringer Ingelheim Investigational Site 35

Hamburg, , Germany

Site Status

Boehringer Ingelheim Investigational Site 36

Hamburg, , Germany

Site Status

Boehringer Ingelheim Investigational Site 37

Hanover, , Germany

Site Status

Boehringer Ingelheim Investigational Site 38

Hanover, , Germany

Site Status

Boehringer Ingelheim Investigational Site 39

Hanover, , Germany

Site Status

Boehringer Ingelheim Investigational Site 40

Heidelberg, , Germany

Site Status

Boehringer Ingelheim Investigational Site 41

Karlsruhe, , Germany

Site Status

Boehringer Ingelheim Investigational Site 42

Koblenz, , Germany

Site Status

Boehringer Ingelheim Investigational Site 43

Leipzig, , Germany

Site Status

Boehringer Ingelheim Investigational Site 44

Mannheim, , Germany

Site Status

Boehringer Ingelheim Investigational Site 45

Mannheim, , Germany

Site Status

Boehringer Ingelheim Investigational Site 46

München, , Germany

Site Status

Boehringer Ingelheim Investigational Site 47

München, , Germany

Site Status

Boehringer Ingelheim Investigational Site 48

München, , Germany

Site Status

Boehringer Ingelheim Investigational Site 49

München, , Germany

Site Status

Boehringer Ingelheim Investigational Site 50

München, , Germany

Site Status

Boehringer Ingelheim Investigational Site 51

Münster, , Germany

Site Status

Boehringer Ingelheim Investigational Site 52

Münster, , Germany

Site Status

Boehringer Ingelheim Investigational Site 53

Münster, , Germany

Site Status

Boehringer Ingelheim Investigational Site 54

Oldenburg, , Germany

Site Status

Boehringer Ingelheim Investigational Site 55

Osnabrück, , Germany

Site Status

Boehringer Ingelheim Investigational Site 56

Saarbrücken, , Germany

Site Status

Boehringer Ingelheim Investigational Site 57

Stuttgart, , Germany

Site Status

Boehringer Ingelheim Investigational Site 58

Stuttgart, , Germany

Site Status

Boehringer Ingelheim Investigational Site 59

Stuttgart, , Germany

Site Status

Boehringer Ingelheim Investigational Site 60

Wuppertal, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1100.1535

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs
NCT00002368 COMPLETED PHASE3
Clinical and Therapeutic Evaluation of the Infection by HIV/AIDS
NCT02191215 COMPLETED
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
NCT00002418 TERMINATED PHASE2
Multiple Dose BE Study With Nevirapine 400mg PR Tablets
NCT02202005 COMPLETED PHASE1
The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease
NCT00002324 COMPLETED PHASE2
Nevirapine + 3TC Based Maintenance Therapy for HIV Infection
NCT03223402 COMPLETED NA
A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir
NCT00001095 COMPLETED PHASE2
A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks
NCT00000914 COMPLETED NA
Zidovudine / Lamivudine + Nevirapine Twice Daily, Versus Tenofovir + Lamivudine + Nevirapine Once Daily in ARV-Naive Patients
NCT00199979 UNKNOWN PHASE3
VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1
NCT06214052 COMPLETED PHASE2
Study to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®) in HIV+ Patients
NCT02184078 COMPLETED PHASE4
Study of Nevirapine and Prednisone to Determine the Safety and Effectiveness in Preventing Nevirapine Associated Rash in Human Immunodeficiency Virus (HIV) Infected Patients
NCT02184299 COMPLETED PHASE4
The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine
NCT00002381 COMPLETED PHASE1
Case-Control Viramune (Nevirapine) Toxicogenomics Study
NCT00310843 COMPLETED
VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients
NCT00561925 COMPLETED PHASE3
Phase 2 Safety and Efficacy Study of Bevirimat Functional Monotherapy in HIV Treatment-Experienced Patients for 2 Weeks*
NCT00511368 COMPLETED PHASE2
Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz.
NCT00158821 COMPLETED PHASE3
Pharmacokinetic Interaction Between Nevirapine and Saquinavir-sgc in HIV-1 Infected Patients
NCT02184286 TERMINATED PHASE1
A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV Disease
NCT00000814 COMPLETED PHASE1
A Two Year Study of the Clinical Efficacy of the Combination of Emtricitabine, Tenofovir, and Nevirapine
NCT00344461 COMPLETED PHASE4
A Study to Demonstrate That Anti-HIV Drug Therapy Can be Stopped Without Causing Viral Resistance, and to Characterize Drug Elimination From the Body
NCT00029341 COMPLETED PHASE2
An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.
NCT00002194 COMPLETED PHASE1
Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive Adults
NCT02182765 TERMINATED PHASE1
A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3
NCT00000859 COMPLETED NA
Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients
NCT00294372 TERMINATED PHASE2